Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Ren Lang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0003-2003-5550; OpenAlex author ID A5101415897. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 8 papers · 2024: 1 paper · 2025: 5 papers · 2026: 5 papers

Papers 28

  1. Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2026.05.001↗
  2. The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDAC. Co-author DOI 10.1038/s41598-026-51645-1↗
  3. Comprehensive comparisons of total pancreatectomy versus pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a double-center, retrospective study. Co-author DOI 10.21037/gs-2025-aw-544↗
  4. Correction: Spatial transcriptomics reveals the heterogeneity and FGG+CRP+ inflammatory cancer-associated fibroblasts replace islets in pancreatic ductal adeno… Co-author DOI 10.3389/fonc.2026.1852367↗
  5. Androgen-induced gene 1 correlates with extracellular vesicle-associated cholesterol metabolism and hepatic metastasis of pancreatic cancer Co-author DOI 10.3748/wjg.121007↗
  6. Radiomics-based histological grading of pancreatic ductal adenocarcinoma using 18F-FDG PET/CT: A two-center study. Co-author DOI 10.1016/j.ejrad.2025.112070↗
  7. A logistic regression model to predict long-term survival for borderline resectable pancreatic cancer patients with upfront surgery. Last author DOI 10.1186/s40644-025-00830-y↗
  8. Integrated multi-omics and single-cell analysis identify SERPINE1 as a key mediator of the inflammatory tumor microenvironment in PDAC. Co-author DOI 10.3389/fimmu.2025.1716878↗
  9. Organ-specific role of neutrophil extracellular traps in shaping the postoperative thrombo-inflammatory niche in pancreatic ductal adenocarcinoma: a multi-mode… Co-author DOI 10.3389/fimmu.2025.1728391↗
  10. Prognostic implications of venous invasion in pancreatic cancer following radical surgical resection: a pathological perspective. Co-author DOI 10.3389/fmed.2025.1613153↗
  11. Influence of sarcopenia on postoperative complications and long-term survival in pancreatic cancer patients undergone pancreaticoduodenectomy. Last author DOI 10.3389/fnut.2024.1434630↗
  12. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-023-11032-9↗
  13. Prognostic value of perioperative serum low-density lipoprotein cholesterol level for postoperative prognosis of pancreatic cancer: a retrospective study. Last author DOI 10.1186/s12944-023-01851-x↗
  14. Derivation and validation of a nomogram model for venous thromboembolism in patients undergoing borderline resectable pancreatic cancer surgery Last author DOI 10.21203/rs.3.rs-2469113/v1↗
  15. Effect of the preoperative prognostic nutritional index on the long-term prognosis in patients with borderline resectable pancreatic cancer after pancreaticodu… Last author DOI 10.3389/fonc.2023.1098459↗
  16. Spatial transcriptomics reveals the heterogeneity and FGG+CRP+ inflammatory cancer-associated fibroblasts replace islets in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1112576↗
  17. A nomogram model to predict the portal vein thrombosis risk after surgery in patients with pancreatic cancer. Last author DOI 10.3389/fsurg.2023.1293004↗
  18. Prognostic Value for Perioperative Serum Total Cholesterol Level on Postoperative Long-Term Prognosis of Pancreatic Cancer: A Retrospective Clinical Study. Last author DOI 10.3390/diagnostics13081402↗
  19. Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.3390/diagnostics13193126↗
  20. MiR-1301-3p Inhibits Epithelial-Mesenchymal Transition via Targeting RhoA in Pancreatic Cancer. Co-author DOI 10.1155/2022/5514715↗
  21. Reconstructing spleno-mesenterico-portal cofluence by bifurcated allogeneic vein in local advanced pancreatic cancer-a feasible method to avoid left-sided port… Last author DOI 10.1002/cam4.4093↗
  22. Without compromising surgical outcomes, neoadjuvant therapy might be a better approach to improve the prognosis of patients with advanced pancreatic cancer. Last author DOI 10.21037/gs-2021-06↗
  23. Prognostic Value of Preoperative NLR and Vascular Reconstructive Technology in Patients With Pancreatic Cancer of Portal System Invasion: A Real World Study. Co-author DOI 10.3389/fonc.2021.682928↗
  24. MiR-374b-5p inhibits KDM5B-induced epithelial-mesenchymal transition in pancreatic cancer. Co-author PMID 34522457↗
  25. Triptolide inhibits pancreatic cancer cell proliferation and migration via down-regulating PLAU based on network pharmacology of Tripterygium wilfordii Hook F. Co-author DOI 10.1016/j.ejphar.2020.173225↗
  26. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1042/bsr20200214↗
  27. Exploring and validating the clinical risk factors for pancreatic cancer in chronic pancreatitis patients using electronic medical records datasets: three coho… First author DOI 10.21037/tcr.2019.11.49↗
  28. Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognost… Co-author DOI 10.1159/000493033↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shaocheng Lyu · 20 shared papers, 2020–2026 · strength 4.86
  2. Qiang He · 7 shared papers, 2021–2026 · strength 1.92
  3. Jincan Huang · 7 shared papers, 2023–2025 · strength 1.75
  4. Han-Xuan Wang · 6 shared papers, 2023–2025 · strength 1.45
  5. Songping Cui · 4 shared papers, 2023–2025 · strength 0.92
  6. Fangfei Wang · 3 shared papers, 2023–2026 · strength 0.78
  7. Jing Wang · 4 shared papers, 2021–2023 · strength 0.77
  8. Zhangyong Ren · 5 shared papers, 2020–2023 · strength 0.75
  9. Xin Zhao · 6 shared papers, 2018–2022 · strength 0.71
  10. Xinxue Zhang · 4 shared papers, 2021–2023 · strength 0.64
  11. Fang-Fei Wang · 2 shared papers, 2026 · strength 0.63
  12. Xin Zhao · 2 shared papers, 2026 · strength 0.61
  13. Qiang He · 3 shared papers, 2021–2025 · strength 0.60
  14. Di Wang · 2 shared papers, 2023–2025 · strength 0.51
  15. Zhe Liu · 3 shared papers, 2020–2023 · strength 0.39
  16. Xin Zhao · 2 shared papers, 2023 · strength 0.38
  17. Qiang He · 3 shared papers, 2020–2022 · strength 0.37
  18. Weiwei Shao · 1 shared paper, 2026 · strength 0.33
  19. Yun-Zhao Luo · 1 shared paper, 2026 · strength 0.32
  20. Tao Jiang · 1 shared paper, 2025 · strength 0.30
  21. Jing Wang · 1 shared paper, 2025 · strength 0.30
  22. Wen-Tao Jiang · 1 shared paper, 2025 · strength 0.28
  23. Di Wang · 1 shared paper, 2025 · strength 0.28
  24. Xu Yang · 1 shared paper, 2025 · strength 0.28
  25. Min-Fu Yang · 1 shared paper, 2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.